Www.ias2013.org Kuala Lumpur, Malaysia, 30 June - 3 July 2013 Comparison of Adherence among Partners’ PrEP Participants on Placebo before and after Release.

Slides:

Advertisements

Similar presentations

9th Advanced HIV Course Aix-en-Provence 2011 Role of ARV as Prevention Martin Fisher Brighton and Sussex University Hospitals, UK.

Advertisements

The operational impact of new World Health Organization (WHO) antiretroviral treatment (ART) guidelines on HIV patient volume and program costs in Kisumu.

Kuala Lumpur, Malaysia, 30 June - 3 July 2013 Improved retention in HIV care following SMS reminders in Mozambique Authors: D. Joseph Davey*,

Referral of participants for HIV follow-up care Africa Centre MDP experiences Presented by: Hlengiwe Ndlovu MDP Clinic coordinator.

Kuala Lumpur, Malaysia, 30 June - 3 July 2013 Home Visits during Pregnancy Enhance Male Partner HIV Testing: A Randomized Clinical Trial.

The Tenofovir Trial in Cambodia In 2004 a randomized trial by investigators from the United States and Australia was planned to assess the safety and efficacy.

The effect of changes in Kenya HIV guidelines on proportion of patients on ART and patient characteristics at initiation in Lumumba Health Centre, Western.

Unmet need for family planning and low rates of dual method protection among men and women attending HIV care and treatment services in Kenya, Namibia.

PMTCT FAILURE: THE ROLE OF MATERNAL AND FACILITY –RELATED FACTORS ICASA Presentation 8 th to 12 th Dec 2013 Onono Maricianah 1, Elizabeth A. Bukusi 1,

Preparing for pre-exposure prophylaxis (PrEP) to prevent HIV infection James Wilton Project Coordinator Biomedical Science of HIV Prevention

Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2013.

HIV in Texas: The Ways Forward Ann Robbins Manager of HIV/STD Prevention and Care Department of State Health Services.

PROMISE Introduction to PROMISE Protocol May 6, 2009.

Characteristics of clients undergoing repeat HIV counseling and testing compared to clients newly-tested for HIV in Nyanza Province Oyaro P, Owuor K, Ng’eno.

KEMRI – UCSF FACES Program June  Launched in September 2004 in Nairobi, Kenya and March 2005 in Kisumu, Nyanza Province, Kenya ◦ PEPFAR funded.

HIV Science Update: From Rome to Addis – Biomedical Prevention Elly T Katabira, FRCP Department of Medicine Makerere University College of Health Sciences.

Are people living with HIV less likely to pass HIV to others if they are on treatment? Exploring the use of treatment as prevention James Wilton Project.

Use of Antivirals in Prevention Oral and Topical Prophylaxis

Uptake of antiretrovirals in a cohort of women involved in high risk sexual behaviour in Kampala, Uganda J.Bukenya, M. Kwikiriza, O. Musana, J. Ssensamba,

Prevention with Positives; Using Multiple Strategies to Involve Persons Living with HIV in Prevention. TASO Uganda. Emmanuel Odeke,

PREVALENCE OF ANAEMIA IN WOMEN AT SCREENING AND FOLLOW-UP IN A MICROBICIDE PHASE III TRIAL Hasinah Asmal, Dinesh Singh, Gita Ramjee HIV Prevention Research.

Integrated Health Programs for Women and Children: Lessons from the Field Dr. Ambrose Misore Project Director, APHIA II Western, PATH’s Kenya Country Program.

LINKAGE OF IDENTIFIED CASES TO HEALTH FACILITIES SERVICE PROVISION TO KEY POPULATIONS KABUSUNZU HC.

The potential role of HIV self-testing within pre-exposure prophylaxis implementation Cheryl Case Johnson World Health Organization, HIV.

Looking back, looking forward: what we know and don’t know about oral PrEP and tenofovir gel for preventing HIV in women Jared Baeten MD PhD Departments.

Looking back, looking forward: what we know and don’t know about oral PrEP and tenofovir gel for preventing HIV in women Jared Baeten MD PhD Departments.

What Is Currently in the Pipeline & What is Ideal for an ARV-based Prevention Candidate? Carl W. Dieffenbach, Ph.D. Director, Division of AIDS, NIAID,

Raymond F. Anton, MD for The COMBINE Study Research Group

The Methods for Improving Reproductive Health in Africa (MIRA) Study SOC PROGRAM Liz Montgomery Women’s Global Health Imperative RTI International GCM.

TREATMENT OF SERO-DISCORDANT COUPLES: IMPLICATIONS FOR YOUNG PEOPLE JJ KUMWENDA (FRCP-UK)

Kuala Lumpur, Malaysia, 30 June - 3 July 2013 Outcomes of newly diagnosed HIV- infected patients referred to care after Provider Initiated.

It is uncertain whether male circumcision (MC) reduces the risk of syphilis among men and women Partners PrEP Study data (n=4,716) analyzed to assess association.

Module 2: Learning Objectives

Translation of research data into programmes and practice: UN Work Plan on Male Circumcision Translation of research data into programmes and practice:

Pharmacist-Managed HIV Pre-Exposure Prophylaxis (PrEP) Clinic: Preliminary Outcomes From an Urban Community Health Clinic Mark T. Sawkin, PharmD, AAHIVP.

AN INTERNATIONAL MULTI-CENTRE, RANDOMISED, DOUBLE- BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF 0.5% AND 2% PRO 2000 GELS FOR.

N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER Pre-exposure Prophylaxis for HIV Prevention Efficacy and the importance of adherence Joanne Stekler,

PreP Adherence Clubs. MSF ART Adherence clubs ART Adherence clubs are long term retention model of care catering for stable ART patients Based on a quick.

Looking Ahead to MTN-017 Ross D. Cranston MD, FRCP Microbicide Trials Network IRMA.

Phase III Microbicide Trials Update Dr. Lut Van Damme IAS Conference Sydney, Australia July 2007.

Factors contributing to diaphragm size change in a Clinical Trial HIV PREVENTION RESEARCH UNIT Govender SM; Mtungwa LN; Manarsingh F; Naidoo VH; Ramjee.

HIV and Women Collaborating Across Borders to Advance the Health of Women IAS 2012 Gina M. Brown, M.D. July 22, 2012.

Non-Medical Staff Knowledge, Beliefs and Practices about HIV and Hepatitis for Injection Drug Users Rowe, KA 1, Tesoriero, JM 1, Heavner, KK 1, Rothman,

Provider Initiated HIV Counseling and Testing Unit 2: Introduction and Rational for PIHCT.

The tipping point: When do placebos become unethical? Bridget Haire.

Maureen Akolo 1, Kimani J 1,2, Osero J 3, Chitwa M 1, Gichuki R 4 Gelmon L 1,2 1.University of Nairobi 2. University of Manitoba 3. Kenyatta University.

Pre-exposure Prophylaxis (PrEP) for HIV Prevention: What’s the Future? Joanne Stekler, MD MPH Assistant Professor of Medicine University of Washington.

PARTNERS DEMONSTRATION PROJECT Integrated delivery of PrEP and ART results in sustained near elimination of HIV transmission in African HIV serodiscordant.

PrEP Scale Up in Kenya: Bridge to Scale Project

PrEP for HIV Prevention

Module 4 (e) Pregnancy and Breast Feeding

HOPE End of Study: Plans and Timeline

Module 4 (c) Stopping PrEP

2017 Key Considerations for adolescents and children & Key populations

Protocol References Section Title 6.2 Entry Visit 5.1

Protocol References Section Title 6.2 Entry Visit 5.1

Quarraisha Abdool Karim, PhD

IMPAACT 2010 Pharmacy, Study Drug, and Concomitant Medication Considerations at Entry No updates.

INTERNATIONAL AIDS SOCIETY Stakeholder consultation to address issues related to tenofovir prophylactic research SUMMARY MEETING UPDATE, MAY 2005, SEATTLE,

PrEP Effectiveness. Preexposure Prophylaxis Translating the Clinical Trials Into Clinical Practice.

MoH leading the design and scale up of PrEP in eswatini

PrEP delivery in public health settings: Successes and barriers

HPTN 082 Uptake and adherence to daily oral PrEP as a primary prevention strategy for young African women: A Vanguard Study.

From Start to Finish: Initial and Ongoing Care for Men Receiving PrEP

IMPLEMETNATION OF PrEP IN SRH SETTINGS (OR CLIMBING A MOUNTAIN)

100 Partners PrEP[5] Efficacy 75% Adherence 81% 80

The 7th EAHSC Pharmacy refill counts and self-reported adherence overestimate adherence to antiretroviral treatment among people living with HIV in Kilimanjaro,

Surmounting PrEP delivery challenges through adaptation of implementation guidelines: lessons learned from HIV care clinics in Kenya Elizabeth M. Irungu,

Bob Holtkamp, Director of Prevention & Outreach

Presentation transcript:

Kuala Lumpur, Malaysia, 30 June - 3 July 2013 Comparison of Adherence among Partners’ PrEP Participants on Placebo before and after Release of Trial Results – Kisumu, Kenya B. Wamuti, J. Odoyo, B. Rono, C. Cohen, E. Bukusi Kenya Medical Research Institute University of Washington University of California, San Franscisco

Kuala Lumpur, Malaysia, 30 June - 3 July 2013 Adherence crucial for success of any clinical drug trial and/or treatment Effective HIV treatment and prevention requires good compliance to medication Reduction of HIV acquisition by the HIV negative individual: PrEP PrEP studies with high adherence show greater efficacy in reduction of transmission Adherence has been the key issue with PrEP INTRODUCTION

Kuala Lumpur, Malaysia, 30 June - 3 July 2013 Partners’ PrEP Kisumu site INTRODUCTION

Kuala Lumpur, Malaysia, 30 June - 3 July arms: Tenofovir, Tenofovir/Emtricitabine (Truvada) and placebo Kisumu participants: 630 HIV sero-discordant couples HIV –ve partner: Randomized to PrEP HIV +ve partner: Not eligible for HAART at enrolment INTRODUCTION

Kuala Lumpur, Malaysia, 30 June - 3 July 2013 Definition: Compliance to once-a-day dose of PrEP Assessed by pill count Blood drug levels not available Strategies to improve adherence 1.Monthly adherence counseling: By nurse counselor, clinician, pharmacist and social worker 2.Pill reminders ADHERENCE

Kuala Lumpur, Malaysia, 30 June - 3 July 2013 July 2011: Release of the preliminary results by the Data Safety Monitoring Board (DSMB) Reduction of HIV transmission 63% (Tenofovir), 75% (Truvada) Recommended re-assignment of placebo participants to active arms BACKGROUND

Kuala Lumpur, Malaysia, 30 June - 3 July 2013 BACKGROUND Tenofovir arm Truvada arm Placebo arm 2011: Re-assignment as per DSMB recommendation Tenofovir/Truvada Study start Study close-out

Kuala Lumpur, Malaysia, 30 June - 3 July 2013 To compare adherence to the study medication before and after release of the preliminary results of the clinical trial among PrEP participants on placebo OBJECTIVE

Kuala Lumpur, Malaysia, 30 June - 3 July 2013 Compared adherence at month 1, 6 and 12 before and after re-randomization Reviewed by pill counts Blood drug levels not yet available METHODS

Kuala Lumpur, Malaysia, 30 June - 3 July 2013 Challenges to adherence: “If I am not sick, aren’t these drugs just accumulating in my system?” Source: METHODS

Kuala Lumpur, Malaysia, 30 June - 3 July 2013 Adherence counseling METHODS

Kuala Lumpur, Malaysia, 30 June - 3 July 2013 Pill reminders METHODS

Kuala Lumpur, Malaysia, 30 June - 3 July 2013 Placebo participant numbers 45 clients not reassigned RESULTS TIME PERIODNo. of participantsPercentage At start of the study (2008)210100% At placebo stop (July 2011) % At re-enrolment (Sep 2011) %

Kuala Lumpur, Malaysia, 30 June - 3 July 2013 Reasons for not being reassigned *Jailed, abnormal renal function, abnormal liver function RESULTS Reasons for IneligibilityNumber Declined participation25 Pregnant4 Not located8 Sero-converted1 Other reasons*10

Kuala Lumpur, Malaysia, 30 June - 3 July 2013 Adherence levels RESULTS Visit MonthAdherence Before Re- randomization Adherence After Re- randomization P-Value 196% %97% % 0.822

Kuala Lumpur, Malaysia, 30 June - 3 July 2013 High adherence reported before and after re- randomization Likely resulted from intensive, ongoing adherence counselling Possibly also from focus on sero-discordant couples Adherence results from this study are encouraging DISCUSSION

Kuala Lumpur, Malaysia, 30 June - 3 July 2013 Develop intensive, cost-effective counselling curricula that result in excellent adherence PrEP demonstration projects - way forward RECOMMENDATION

Kuala Lumpur, Malaysia, 30 June - 3 July 2013 ACKNOWLEDGEMENTS 1.Partners‘ PrEP Kisumu study participants, site staff 2.Kenya Medical Research Institute – Research Care and Training Program 3.University of Washington, USA 4.University of California San Franscisco, USA 5.Gilead (study drug) 6.Bill and Melinda Gates Foundation (study funder)